

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5412489

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
TARO PHARMACEUTICALS NORTH AMERICA, INC.		02/17/2019
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	TARO PHARMACEUTICALS INC.	
<b>Street Address:</b>	130 EAST DR	
<b>City:</b>	BRAMPTON, ONTARIO	
<b>State/Country:</b>	CANADA	
<b>Postal Code:</b>	L6T 1C1	
<b>PROPERTY NUMBERS Total: 6</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	7799331	
<b>Patent Number:</b>	8206727	
<b>Patent Number:</b>	8461139	
<b>Patent Number:</b>	9365609	
<b>Patent Number:</b>	8277780	
<b>Patent Number:</b>	8715624	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(609)514-9779	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	609-720-5622	
<b>Email:</b>	general.ip.mailbox@sunpharma.com	
<b>Correspondent Name:</b>	SUN PHARMA	
<b>Address Line 1:</b>	2 INDEPENDENCE WAY	
<b>Address Line 2:</b>	INTELLECTUAL PROPERTY DEPT.	
<b>Address Line 4:</b>	PRINCETON, NEW JERSEY 08540	
<b>ATTORNEY DOCKET NUMBER:</b>	TNA TRANSFER TO TCAN	
<b>NAME OF SUBMITTER:</b>	STACI BONIN	
<b>SIGNATURE:</b>	/Staci Bonin/	
<b>DATE SIGNED:</b>	03/08/2019	

**Total Attachments: 3**

source=TNA Asset Transfer - Patent Assignment - TNA to TCAN#page1.tif

source=TNA Asset Transfer - Patent Assignment - TNA to TCAN#page2.tif

source=TNA Asset Transfer - Patent Assignment - TNA to TCAN#page3.tif

## PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT (the "Assignment") is entered into by and between Taro Pharmaceuticals North America, Inc. ("Assignor"), a Cayman Islands corporation and Taro Pharmaceuticals Inc. ("Assignee"), having an address at 130 East Dr, Brampton, Ontario L6T 1C1, Canada, is effective as of April 1, 2017 ("Effective Date").

WHEREAS, Assignor is the owner of the entire right, title and interest in, to and under the patents and/or patent applications set forth in Schedule A attached hereto, including all design patents, divisionals, continuations, continuations-in-part, re-examinations, reissues, renewals, extensions, registrations, and supplemental protection certificates and the like of any of the foregoing (the "Patents"), and has the unrestricted right to sell, assign and transfer such patents and/or patent applications; and

WHEREAS, Assignor desires to assign to Assignee, and Assignee desires to receive, Assignor's entire rights, title and interest in and to the Patents.


NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained in this Assignment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Assignor hereby conveys, sells, assigns, and transfers to Assignee, and Assignee hereby accepts, Assignor's entire right, title and interest in, to and under the Patents, including the patents and/or patent applications set forth on Schedule A hereto, including, but not limited to, all issuances, design patents, divisions, continuations, substitutions, continuations-in-part, reexaminations, reissues, additions, renewals, utility models, extensions, post grant reviews, *inter partes* reviews, foreign counterparts, and the like, and all rights of any kind accruing under any of the foregoing provided by applicable laws, by international treaties and conventions and otherwise throughout the world, and any and all accounts, contract rights, warranties, litigation claims and rights, including all rights to claim priority on the basis of any of the Patents and the right to sue for and collect upon all claims for profits and damages as a result of past infringement, if any, related to any of the foregoing, in each case whether now existing or hereafter acquired or created, whether owned, leased or licensed beneficially or of record and whether owned, leased or licensed individually, jointly or otherwise, together with the products and proceeds thereof (including license royalties and the proceeds of infringement suits), all payments and other distributions with respect thereto (all of the foregoing herein collectively referred to as the "Patent Rights").
2. Assignor hereby authorizes the Commissioners for Patents and Trademarks of the U.S. Patent and Trademark Office and other empowered officials of relevant intellectual property offices and other governmental or regulatory authorities in each jurisdiction other than the United States, to record the transfer to Assignee of the Assignor's entire rights, title and interests in, to, and under the Patent Rights, and to issue all future registrations and other rights relating to such Patent Rights to Assignee.
3. Assignor hereby covenants that, from time to time after the delivery of this instrument, at Assignee's request and without further consideration, Assignor will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further acts, deeds, conveyances, transfers, assignments, oaths, declarations, powers of attorney and assurances required to convey and transfer to Assignee, and put Assignee in possession of, any of the Patent Rights.

IN WITNESS WHEREOF this Patent Assignment Agreement is executed by, and will be binding upon, Assignor and Assignee and their respective successors and/or assigns for the uses and purposes set forth herein, effective immediately upon the Effective Date.


**Assignor**

**Taro Pharmaceuticals North America, Inc.**

By:   
Name: RICHARD PAUL WOODHOUSE  
Title: GENERAL MANAGER  
Date: 17 / 2 / 2019

**Assignee**

**Taro Pharmaceuticals Inc.**

By:   
Name: Stephen J. Manzano  
Title: GVP, General Counsel,  
Date: Secretary & Corporate  
Compliance 2 / 28 / 2019

**Schedule A  
Patents**

Country	Patent Number	Issue Date	Title	Status
New Zealand	566117	10 Oct 2011	ORAL SUSPENSION OF PREDNISOLONE ACETATE	GRANTED
USA	7,799,331	21 Sep 2010	ORAL SUSPENSION OF PREDNISOLONE ACETATE	GRANTED
USA	8,206,727	26 Jun 2012	ORAL SUSPENSION OF PREDNISOLONE ACETATE	GRANTED
USA	8,461,139	11 Jun 2013	ORAL SUSPENSION OF PREDNISOLONE ACETATE	GRANTED
USA	9,365,609	14 Jun 2016	PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE	GRANTED
USA	8,277,780	02 Oct 2012	STABLE LIQUID DESOXIMETHASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY	GRANTED
USA	8,715,624	06 May 2014	STABLE LIQUID DESOXIMETHASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY	GRANTED
Canada	2,609,579	19 Aug 2014	STABLE LIQUID DESOXIMETHASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY	GRANTED